Table 2.
VEGF binder | Thermophoresis KD (nM) |
SPR KD (nM) |
---|---|---|
mAb2_WT | 3.7 ± 1.1 | 4.22 |
mAb2_SL50K | 8.3 ± 1.4 | 7.88 |
mAb2_SL50D | 4.4 ± 1.3 | 4.68 |
mAb2_SL52R | 3.2 ± 1.8 | 2.86 |
mAb2_VH100R | NB | NB |
mAb2_FH101P | NB | NB |
mAb2_SL50K_SH21R_SH85R | 57.1 ± 6.2 | – |
mAb2_SL50K_FH101P | NB | – |
mAb2_SL50K_SH21R_SH85R_FH101P | NB | – |
mAb2_SL52R_FH101P | NB | – |
mAb2_SL52R_SH21R_SH85R_FH101P | NB | – |
Bevacizumab (Avastin) | 4.8 ± 1.6 | ~ 1.8–20 [33], [46] |